High-yield points
- Subtypes and drivers:
- ACP: childhood, cystic, calcified, CTNNB1.
- PCP: adult, solid, BRAF V600E, which responds to BRAF–MEK inhibition (94%) .
- Hypothalamic involvement (Puget grade) predicts morbidity. Plan the resection by grade .
- Spare the posterior hypothalamus:
- Gains: better quality of life and less obesity.
- Cost: lower PFS, but survival stays around 100% .
- Subtotal resection plus radiotherapy ≈ GTR for control: 5-year PFS 73% vs. 77%; subtotal resection alone, 43% .
- Limited surgery plus proton therapy (RT2CR):
- Control: 3-year PFS 97%.
- Benefit over photons: better cognition, not better survival .
- Early post-radiation cyst growth is usually benign. Don't call it progression .
Landmark papers
- KRANIOPHARYNGEOM 2007 (Bogusz et al., Endocr Connect 2019): 169 children. Overall survival was 100%, and posterior hypothalamus-sparing surgery gave better quality of life and less obesity at the price of lower progression-free survival .
- RT2CR (Merchant et al., Lancet Oncol 2023): a single-arm phase 2 study (94 children aged 0–21) of limited surgery plus 54 Gy proton therapy. 3-year PFS was 96.8% and overall survival 100% .
- BRAF–MEK inhibition (Brastianos et al., N Engl J Med 2023): a phase 2 study of vemurafenib plus cobimetinib before radiation in 16 patients with papillary craniopharyngioma. 15 of 16 (94%) had a durable partial response or better .
Craniopharyngioma is a histologically benign epithelial tumor of the sellar–suprasellar region. Long-term survival is high, but it is one of the most morbid tumors in pediatric neurosurgery, because its neighbors are:
- the optic chiasm;
- the pituitary stalk;
- the hypothalamus.
The modern goal is tumor control with hypothalamic preservation, not gross total resection at any cost .
Biology and presentation
- Two subtypes :
- Adamantinomatous (ACP):
- Age: the childhood form; bimodal peaks at 5–15 and 45–60 years.
- Appearance: predominantly cystic, often calcified.
- Driver: CTNNB1 (β-catenin) mutations, in 96% of ACPs.
- Papillary (PCP):
- Age: almost exclusively adults.
- Appearance: solid.
- Driver: BRAF V600E, in 95% of PCPs.
- Presentation :
- raised ICP, often from hydrocephalus;
- visual impairment;
- endocrine deficits: growth failure, diabetes insipidus, delayed puberty.
- Imaging: MRI, with CT for the calcification that is characteristic of ACP (see caveats).
- Workup before surgery (see caveats):
- endocrine evaluation and replacement, especially cortisol, before any operation;
- visual fields and acuity;
- hypothalamic grading on MRI.
Hypothalamic involvement drives outcome
- Puget grading (66 retrospective and 22 prospective children) :
- The grades:
- grade 0: no hypothalamic involvement;
- grade 1: the tumor abuts or displaces the hypothalamus;
- grade 2: the hypothalamus is invaded or no longer identifiable.
- What predicted poor outcome: preoperative MRI grade, clinical hypothalamic dysfunction and surgeon experience.
- Grade-based strategy: in the prospective cohort the strategy was GTR 20%, complete resection avoiding the hypothalamus 40%, subtotal resection 40%, with radiotherapy for any residual tumor.
- Result: no new hyperphagia, morbid obesity or behavioral dysfunction.
- KRANIOPHARYNGEOM 2007 (169 children) :
- Survival: overall survival was 100% in every subgroup.
- The cost of injuring the posterior hypothalamus: surgical lesions of the anterior plus posterior hypothalamus caused higher BMI and worse quality of life than anterior-only or no lesions.
- The trade-off: posterior hypothalamus-sparing surgery means better quality of life and less obesity, at the price of lower progression-free survival.
- Hypothalamic obesity, fatigue and psychosocial deficits are the main long-term burden .
Surgery
- Extent of resection versus radiotherapy (systematic review, 531 children) :
- 5-year progression-free survival (PFS):
- GTR: 77%;
- subtotal resection plus radiotherapy: 73% (no significant difference);
- subtotal resection alone: only 43%.
- Implication: planned limited resection plus radiotherapy controls the tumor as well as GTR when GTR would injure the hypothalamus.
- Approach (meta-analysis, 2,955 transcranial vs. 373 transsphenoidal patients) :
- Transsphenoidal patients did better: more GTR and less morbidity.
- But the groups weren't comparable: they started with smaller, more intrasellar tumors.
- Transcranial approaches suit:
- large tumors with lateral extension;
- tumors that engulf vessels;
- tumors with heavy peripheral calcification.
- Expanded endoscopic endonasal approaches now reach many suprasellar, retrochiasmatic tumors (see caveats).
- Cyst control:
- Ommaya catheter: one of the individualized surgical options before proton therapy in RT2CR . It decompresses large cysts and allows staged treatment (see caveats).
- Intracystic therapy (for example interferon alpha) is an option for monocystic ACP .
- Hydrocephalus: cyst decompression or tumor removal often relieves it; otherwise a shunt (see caveats).
Radiotherapy
- RT2CR (phase 2: limited surgery plus 54 Gy proton therapy, 94 children aged 0–21) :
- Control: 3-year PFS 96.8% and overall survival 100%.
- Complications at 5 years:
- necrosis, 2%;
- severe vasculopathy, 4%;
- permanent neurologic deficits, 3%;
- visual decline in 7% of those with normal baseline vision.
- Comparison with photons: survival was no better than a historical photon cohort, but cognitive outcomes were better.
- KRANIOPHARYNGEOM 2007 radiotherapy (99 of 290 patients) :
- Event-free survival at 5 years: 92% after protons vs. 91% after photons, compared with 37% for the whole cohort.
- Conclusion: radiotherapy of any type is very effective after hypothalamus-sparing surgery. A specific late benefit of protons is not yet proven.
- KiProReg (74 children, proton therapy) :
- 3-year outcomes: overall survival 98.2%, PFS 94.7%, and cystic failure-free survival 76.8%.
- Early cyst enlargement after radiotherapy is usually asymptomatic and self-limiting. Don't mistake it for progression within the first 12 months.
Targeted therapy
- Papillary (BRAF V600E): vemurafenib plus cobimetinib before radiation (16 patients, phase 2) :
- Response: 15 of 16 (94%) had a durable partial response or better.
- Shrinkage: median volume reduction 91%.
- Population: adults, because PCP is rare in children.
- Adamantinomatous: no proven targeted therapy. Trials of agents aimed at ACP biology are ongoing (see caveats).
Related topics
- Sellar and Suprasellar Lesions: other sellar lesions and the endocrine workup.
- Optic Pathway Gliomas: the other suprasellar tumor threatening vision and the hypothalamus.
References
- Müller HL, Merchant TE, Warmuth-Metz M, et al. Craniopharyngioma. Nat Rev Dis Primers 2019;5(1):75. doi:10.1038/s41572-019-0125-9. PMID 31699993. verified
- Bogusz A, Boekhoff S, Warmuth-Metz M, et al. Posterior hypothalamus-sparing surgery improves outcome after childhood craniopharyngioma. Endocr Connect 2019;8(5):481–492. doi:10.1530/EC-19-0074. PMID 30925462. verified
- Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 2014;46(2):161–165. doi:10.1038/ng.2868. PMID 24413733. verified
- Puget S, Garnett M, Wray A, et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg 2007;106(1 Suppl):3–12. doi:10.3171/ped.2007.106.1.3. PMID 17233305. verified
- Clark AJ, Cage TA, Aranda D, et al. A systematic review of the results of surgery and radiotherapy on tumor control for pediatric craniopharyngioma. Childs Nerv Syst 2013;29(2):231–238. doi:10.1007/s00381-012-1926-2. PMID 23089933. verified
- Elliott RE, Jane JA Jr, Wisoff JH. Surgical management of craniopharyngiomas in children: meta-analysis and comparison of transcranial and transsphenoidal approaches. Neurosurgery 2011;69(3):630–643. doi:10.1227/NEU.0b013e31821a872d. PMID 21499159. verified
- Merchant TE, Hoehn ME, Khan RB, et al. Proton therapy and limited surgery for paediatric and adolescent patients with craniopharyngioma (RT2CR): a single-arm, phase 2 study. Lancet Oncol 2023;24(5):523–534. doi:10.1016/S1470-2045(23)00146-800146-8). PMID 37084748. verified
- Frassanito P, Massimi L, Bianchi F, et al. Targeted treatment of pediatric craniopharyngioma: lesson learnt after 20-year experience with intracystic interferon alpha. Adv Tech Stand Neurosurg 2025;55:93–110. doi:10.1007/978-3-031-90762-3_5. PMID 40608102. verified
- Friedrich C, Boekhoff S, Bischoff M, et al. Outcome after proton beam therapy versus photon-based radiation therapy in childhood-onset craniopharyngioma patients: results of KRANIOPHARYNGEOM 2007. Front Oncol 2023;13:1180993. doi:10.3389/fonc.2023.1180993. PMID 37965466. verified
- Bischoff M, Khalil DA, Frisch S, et al. Outcome after modern proton beam therapy in childhood craniopharyngioma: results of the prospective registry study KiProReg. Int J Radiat Oncol Biol Phys 2024;120(1):137–148. doi:10.1016/j.ijrobp.2024.03.015. PMID 38492813. verified
- Brastianos PK, Twohy E, Geyer S, et al. BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas. N Engl J Med 2023;389(2):118–126. doi:10.1056/NEJMoa2213329. PMID 37437144. verified
Verification (2026-11-17):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
Caveats:
- The following are standard practice, not drawn from the cited abstracts:
- preoperative endocrine evaluation and stress-dose steroids;
- hydrocephalus as the usual cause of raised ICP, and the specific endocrine deficits listed (reference 1's abstract names only raised ICP, visual impairment and endocrine deficiencies);
- the benefits of an Ommaya cyst catheter;
- CT for calcification;
- expanded endoscopic endonasal reach;
- shunting for persistent hydrocephalus;
- ongoing ACP-targeted trials.
- The Puget grade definitions are paraphrased standard descriptions; the abstract (4) describes "preoperative MRI grade" without listing the grades.
- RT2CR's use of an Ommaya catheter is one of several individualized surgical options in reference 7.
- The figure is an original schematic.